ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2265

Autoimmune RNA Dysregulation and Seizures: Therapeutic Prospects in Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 1201

Autoimmune Serologies, Cell-Bound Complement Activation Products, and Autoimmune Rheumatic Disease Symptoms After COVID-19 Infection
Abstract Number: 1223

Autoimmune Thyroid Disease Associates with Hand Pain in Older Adults in the Third National Health and Nutrition Examination Survey
Abstract Number: 2240

Autoimmunity Against Melanoma Differentiation-Associated Protein 5 Advances Acute Lung Injury to Interstitial Lung Disease in Mice
Abstract Number: 0149

Autoinflammatory Diseases Associated with NOD2 and Other Concurrent Genetic Mutations
Abstract Number: 0972

Automated Joint Space Width Measurement for Hand Osteoarthritis: A Deep Learning Approach
Abstract Number: 1220

Autonomic Dysfunction in Sjogren’s Disease
Abstract Number: 0793

Autonomic Nervous System Dysfunction Common Among Patients with Long COVID: An Exploratory Evaluation
Abstract Number: 2020

Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease
Abstract Number: 1154

Axial Spondyloarthritis: Profiling of MiRNAs in Peripheral Blood Mononuclear Cells
Abstract Number: 0958

Azathioprine Metabolite Levels and Outcomes During Pregnancies in Women with Rheumatic Disease
Abstract Number: 1868

B Cell Count in Juvenile Dermatomyositis: A Biomarker of Disease
Abstract Number: 0159

B Cell Phenotype in Adult Patients with Idiopathic Inflammatory Myositis (IIM) Before and After Belimumab
Abstract Number: 0011

B Cell Subsets Contributing to the Autoreactive Plasma Cell Pool in Lyn-/- Mice
Abstract Number: 0780

B-cell Reconstitution Is Associated with COVID-19 Booster Vaccine Responsiveness in Previously Seronegative Rituximab Treated Rheumatic Disease Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].